Therefore, it may be possible that the application of new therapies to target the epigenetic machinery of cancer cells could be used to switch resistant cancer cells to more sensible phenotypes, to promote E2F1-dependent apoptosis in p53-defiant tumors, to reduce cancer-initiating cells (CICs), to prevent metastatic pathway activities and/or to sensitize tumor cells to radiotherapy.11 The gene discussed is E2F1; the disease is cancer.